Acurx Pharmaceuticals, Inc. New York

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

Major finding provides mechanistic explanation for ibezapolstat's (IBZ) selectivity in that the predicted bactericidal interaction between IBZ and its target DNA pol IIIC is conserved across most of the Bacillota phylum, including C. difficile, while certain beneficial taxa are naturally resistant to IBZ, allowing regrowth of resistant microbes known to confer health benefitsThis study used in silico methods to better interpret the narrower than expected ibezapolstat (IBZ) spectrum of activity observed in human trials, which included increased proportion of certain key gut microbiota of the Bacillota phylumIBZ susceptibility of human commensal (nonpathogenic) microbiota was predicted using genomic analysis and a phylogenetic tree construction of the IBZ target enzyme, pol IIICPreparation continues to advance IBZ into international Ph3 clinical trials for treatment of CDIIBZ has previously been granted FDA QIDP and Fast-Track Designation and has received SME (Small and Medium-sized Enterprise) designation by the EMAView original content:https://www.prnewswire.co.uk/news-releases/acurx-announces-publication-of-positive-results-from-an-in-silico-study-predicting-the-microbiome-restorative-potential-of-ibezapolstat-in-the-treatment-of-cdi-302382688.html